US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

First Trust NYSE Arca Biotechnology Index Fund

268.15

-3.0800-1.14%

Post-market: 268.150.00000.00%19:30 EDT

Volume:23.51K

Turnover:6.32M

Market Cap:2.91B

PE:31.38

High:271.63

Open:271.63

Low:267.73

Close:271.23

52wk High:274.99

52wk Low:173.98

Shares:10.85M

Float Shares:10.85M

Volume Ratio:0.78

T/O Rate:0.22%

Dividend:- -

Dividend Rate:- -

EPS(TTM):8.55

EPS(LYR):37.75

ROE:19.96%

ROA:-0.16%

PB:1.04

PE(LYR):7.10

Loading ...

Overview Company News Filings

Patent Cliffs Drive Pharma Expansion as Biotech M&A and IPO Markets Stage a Comeback

Corcept Chief Business Officer Gary Charles Robb Sells 10,000 Shares for $1.16 Million

BMO starts Exelixis at Market Perform into patent cliff

Bruker Nano EVP, President Mark Munch Disposes of 4,984 Bruker Shares for $288,636.8

Genprex selects manufacturing organization for diabetes gene therapy

Corcept Therapeutics Incorporated : Truist Securities Assumes Coverage with Buy Rating; Target Price $164 vs $50

THOMSON REUTERS

Alkermes SVP, Chief Commercial Officer Christian Todd Nichols Sells 7,576 Shares for $374,301.99

CANbridge Wins Taiwan NHIA Reimbursement for Rare Disease Drug Livmarli

NEO Battery Raises $4 Million to Expand South Korean Battery Manufacturing

Bruker Board Declares Quarterly Cash Dividend for Shareholders

Bruker Declares Quarterly Cash Dividend of $0.05 a Share

Press Release: Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Corcept Chief Development Officer William Guyer Disposes of Common Shares Worth $1.85 Million

Alkermes Cuts Interest Spreads on $1.52 Billion Term Loan Facilities Via Credit Agreement Amendment

Alkermes - Enters Amendment No. 1 to Credit Agreement on August 12, 2026 - SEC Filing

THOMSON REUTERS

Alkermes - Amendment Reduces Interest Rate Spread Under Tla by 0.75% and Tlb by 0.50% - SEC Filing

THOMSON REUTERS

NeoGenomics Announces Planned Transition of General Counsel Role

Neurogene Advances Rett Gene Therapy Program and Extends Cash Runway to 2029

Veracyte (VCYT) Dropped, So What Is Behind The Latest Attention?

Simply Wall St.

Bruker Expands Atinary Collaboration, Makes Minority Investment in AI R&D Firm

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/FBT/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"FBT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBT\",,,,,undefined,":{"symbol":"FBT","market":"US","secType":"STK","nameCN":"First Trust NYSE Arca Biotechnology Index Fund","latestPrice":268.15,"timestamp":1789761600000,"preClose":271.23,"halted":0,"volume":23507,"hourTrading":{"tag":"盘后","latestPrice":268.15,"preClose":268.15,"latestTime":"19:30 EDT","volume":17,"amount":4553.29,"timestamp":1789774206683,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.011355675994543526,"floatShares":10850002,"shares":10850002,"eps":8.545272,"marketStatus":"Market Closed","change":-3.08,"latestTime":"09-18 16:00:00 EDT","open":271.63,"high":271.63,"low":267.73,"amount":6319864.942380001,"amplitude":0.014379,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":8.545272,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789977600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":271.23,"sharesOutstanding":11450002,"nav":270.95,"aum":2953355541.9,"bidAskSpread":0.00095,"preHourTrading":{"tag":"盘前","latestPrice":271.23,"preClose":271.23,"latestTime":"07:36 EDT","volume":4,"amount":1084.9316,"timestamp":1789731363239,"change":0,"changeRate":0,"amplitude":0.000043},"postHourTrading":{"tag":"盘后","latestPrice":268.15,"preClose":268.15,"latestTime":"19:30 EDT","volume":17,"amount":4553.29,"timestamp":1789774206683,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7794563330839,"impliedVol":0.2045,"impliedVolPercentile":0.4223},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBT\",,,,,undefined,":{"symbol":"FBT","floatShares":10850002,"roa":"-0.16%","roe":"19.96%","lyrEps":37.754725,"volumeRatio":0.7794563330839,"shares":10850002,"dividePrice":0,"high":271.63,"amplitude":0.014379,"preClose":271.23,"low":267.73,"week52Low":173.975,"pbRate":"1.04","psRate":"701.87","week52High":274.99,"institutionHeld":0,"latestPrice":268.15,"eps":8.545272,"divideRate":0,"volume":23507,"delay":0,"ttmEps":8.545272,"open":271.63,"prevYearClose":206.52,"prevWeekClose":261.85,"prevMonthClose":267.15,"prevQuarterClose":247.89,"fiveDayClose":261.85,"twentyDayClose":268.125,"sixtyDayClose":237.29},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FBT\",params:#limit:5,,,undefined,":[{"date":"2024-12-13","symbol":"FBT","amount":1.1726,"announcedDate":"2024-12-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-13","defaultRemindTime":1734100200000,"name":"First Trust NYSE Arca Biotechnology Index Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-31","payableDate":"2024-12-13","currency":"USD","dateTimestamp":1734066000000,"payDate":"2024-12-31"},{"market":"US","date":"2022-01-10","symbol":"FBT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1641790800000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2021-12-30","symbol":"FBT","amount":2.2136,"defaultRemindTime":1640874600000,"name":"First Trust NYSE Arca Biotechnology Index Fund","recordDate":"2022-01-10","payableDate":"2021-12-31","currency":"USD","type":"dividend","dateTimestamp":1640840400000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FBT\",market:\"US\",,,undefined,":[{"executeDate":"2021-12-30","recordDate":"2021-12-31","paymentDate":"2022-01-10","value":2.2136,"currency":"USD"},{"executeDate":"2024-12-13","recordDate":"2024-12-13","paymentDate":"2024-12-31","value":1.1726,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FBT\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FBT\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1184678054","title":"Patent Cliffs Drive Pharma Expansion as Biotech M&A and IPO Markets Stage a Comeback","url":"https://stock-news.laohu8.com/highlight/detail?id=1184678054","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184678054?lang=en_us&edition=fundamental","pubTime":"2026-08-19 16:15","pubTimestamp":1787127336,"startTime":"0","endTime":"0","summary":"Andy Acker, Portfolio Manager for healthcare and biotech strategies at Janus Henderson Investors, notes that despite interest rates remaining higher than markets anticipated at the start of the year,...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PBE","IBB","MRNX","MRNY","BK4588","QSML","BBP","FBT","IWO","IBBJ","BK4585","BK4582","IAI","BIB","JDOC","SPCK","IJT","BBC","BIS","GTPE","IYG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660371492","title":"Corcept Chief Business Officer Gary Charles Robb Sells 10,000 Shares for $1.16 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2660371492","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660371492?lang=en_us&edition=fundamental","pubTime":"2026-08-19 04:31","pubTimestamp":1787085063,"startTime":"0","endTime":"0","summary":"Corcept Chief Business Officer Gary Charles Robb sells 10,000 shares for $1.16 millionCorcept Therapeutics Chief Business Officer Gary Charles Robb sold 10,000 common shares on Aug. 17.Sale priced at ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDLc47Ccv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept Chief Business Officer Gary Charles Robb Sells 10,000 Shares for $1.16 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBT","PSCH","CORT","LU1559883803.SGD","LU0566484027.USD","BK4532","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660492411","title":"BMO starts Exelixis at Market Perform into patent cliff","url":"https://stock-news.laohu8.com/highlight/detail?id=2660492411","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660492411?lang=en_us&edition=fundamental","pubTime":"2026-08-19 04:30","pubTimestamp":1787085023,"startTime":"0","endTime":"0","summary":"BMO Capital initiated coverage of Exelixis (EXEL) with a Market Perform rating and $54 price target Exelixis is anchored by cabozantinib, a “durabl...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bmo-starts-exelixis-at-market-perform-into-patent-cliff-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bmo-starts-exelixis-at-market-perform-into-patent-cliff-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PBPH","PJP","FTXH","JDOC","LU1992135399.USD","RSPH","LU2322448957.HKD","BMO","BME","TMED","BK4585","BK4139","BK4207","GSKH","IBB","LU1992135472.HKD","SYNB","BK4588","PTH","MEDX","IYH","LU2272731600.USD","USRD","FBT","XPH","BK4532","RXD","RXL","FHLC","IHE","EXEL","APXH","LU2322448791.USD","LU2473716301.USD","TRUH","IE00B5TLWC47.USD","LU2272731865.HKD","LU2272731782.SGD","BBH","FXH","MEDI","AZNH","CURE","PPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660494087","title":"Bruker Nano EVP, President Mark Munch Disposes of 4,984 Bruker Shares for $288,636.8","url":"https://stock-news.laohu8.com/highlight/detail?id=2660494087","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660494087?lang=en_us&edition=fundamental","pubTime":"2026-08-19 04:16","pubTimestamp":1787084184,"startTime":"0","endTime":"0","summary":"Bruker Nano EVP, President Mark Munch disposes of 4,984 Bruker shares for $288,636.8Mark Munch, executive vice president and president of Bruker Nano, reduced his Bruker holdings to 134,806 shares.Sold 2,000 shares on Aug. 14 at USD 57.6 under a 10b5-1 plan.Disposed of 2,984 shares on Aug. 15 at USD 57.7 to cover tax withholding tied to RSU vesting.Exercised options for 2,000 shares on Aug. 14 at USD 22.19.Received 14,443 restricted stock units on Aug. 15 at USD 0.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bruker Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 18, 2","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDL6tynRH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Bruker Nano EVP, President Mark Munch Disposes of 4,984 Bruker Shares for $288,636.8","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRKR","LU1815336091.USD","TINY","BK4121","LU0757428866.USD","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660461015","title":"Genprex selects manufacturing organization for diabetes gene therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2660461015","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660461015?lang=en_us&edition=fundamental","pubTime":"2026-08-18 19:10","pubTimestamp":1787051418,"startTime":"0","endTime":"0","summary":"Genprex (GNPX) has entered into a development and manufacturing agreement with a U.S. based clinical and commercial Contract Development and Manufa...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/genprex-selects-manufacturing-organization-for-diabetes-gene-therapy-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/genprex-selects-manufacturing-organization-for-diabetes-gene-therapy-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FBT","GNOM","GNPX","SYNB","TBXU","BK4588","IBB","EES","LFSC","CNCR","BK4585","IBBQ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660619704","title":"Corcept Therapeutics Incorporated : Truist Securities Assumes Coverage with Buy Rating; Target Price $164 vs $50","url":"https://stock-news.laohu8.com/highlight/detail?id=2660619704","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660619704?lang=en_us&edition=fundamental","pubTime":"2026-08-18 19:04","pubTimestamp":1787051049,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nFWN44F0P6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4532","BK4007","CORT","LU1559883803.SGD","LU0566484027.USD","PSCH","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660430568","title":"Alkermes SVP, Chief Commercial Officer Christian Todd Nichols Sells 7,576 Shares for $374,301.99","url":"https://stock-news.laohu8.com/highlight/detail?id=2660430568","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660430568?lang=en_us&edition=fundamental","pubTime":"2026-08-18 06:54","pubTimestamp":1787007262,"startTime":"0","endTime":"0","summary":"Alkermes SVP, Chief Commercial Officer Christian Todd Nichols sells 7,576 shares for $374,301.99Alkermes SVP, Chief Commercial Officer Christian Todd Nichols sold 7,576 ordinary shares on Aug. 17, 202","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDLbv4Lk0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Alkermes SVP, Chief Commercial Officer Christian Todd Nichols Sells 7,576 Shares for $374,301.99","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","IBRN","MEDX","BK4139","FBT","ALKS","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660343035","title":"CANbridge Wins Taiwan NHIA Reimbursement for Rare Disease Drug Livmarli","url":"https://stock-news.laohu8.com/highlight/detail?id=2660343035","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660343035?lang=en_us&edition=fundamental","pubTime":"2026-08-18 06:38","pubTimestamp":1787006327,"startTime":"0","endTime":"0","summary":"CANbridge Pharmaceuticals Inc. ( ($HK:1228) ) has shared an update. CANbridge Pharmaceuticals Inc. announced that its rare disease drug Livmarli ha...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/canbridge-wins-taiwan-nhia-reimbursement-for-rare-disease-drug-livmarli?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/canbridge-wins-taiwan-nhia-reimbursement-for-rare-disease-drug-livmarli?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FBT","BK4585","IBB","IBBQ","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659935124","title":"NEO Battery Raises $4 Million to Expand South Korean Battery Manufacturing","url":"https://stock-news.laohu8.com/highlight/detail?id=2659935124","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659935124?lang=en_us&edition=fundamental","pubTime":"2026-08-15 05:23","pubTimestamp":1786742633,"startTime":"0","endTime":"0","summary":"An announcement from NEO Battery Materials Ltd ( ($TSE:NBM) ) is now available. NEO Battery Materials Ltd. has closed a non-brokered private placem...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neo-battery-raises-4-million-to-expand-south-korean-battery-manufacturing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neo-battery-raises-4-million-to-expand-south-korean-battery-manufacturing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0012050646.USD","NEO","LU0106261612.USD","BK4196","BK4121","UYM","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659121403","title":"Bruker Board Declares Quarterly Cash Dividend for Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2659121403","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659121403?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:58","pubTimestamp":1786741083,"startTime":"0","endTime":"0","summary":"The latest update is out from Bruker ( ($BRKR) ). On August 14, 2026, Bruker Corporation’s Board of Directors declared a quarterly cash dividend of...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bruker-board-declares-quarterly-cash-dividend-for-shareholders?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bruker-board-declares-quarterly-cash-dividend-for-shareholders?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","TINY","BK4121","LU0757428866.USD","BK4588","BRKR","VIG","LU1815336091.USD","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659129910","title":"Bruker Declares Quarterly Cash Dividend of $0.05 a Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2659129910","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659129910?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:23","pubTimestamp":1786738996,"startTime":"0","endTime":"0","summary":"Bruker declares quarterly cash dividend of $0.05 a shareBruker declared a quarterly cash dividend of USD 0.05 per share on its common stock.Dividend payable Oct. 7, 2026, to shareholders of record at ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL69wb3J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBT","LU0757428866.USD","TINY","BK4121","LU1815336091.USD","BRKR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162947","title":"Press Release: Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162947","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162947?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651500,"startTime":"0","endTime":"0","summary":"clinical trial were presented at the 2026 European Hematology Association.  Annual Meeting. Data presented reinforced vispa-cel is the only. single-dose, off-the-shelf therapy to demonstrate deep and durable. responses on par with autologous CAR-T cell therapies in second-line . large B cell lymphoma . Efficacy and safety data in 2L LBCL. patients who had received a single dose of 80 million optimized vispa-cel. -- Optimized vispa-cel is defined as cells from a donor younger than 30. years old with at least two matched human leukocyte antigen  alleles. between patient and donor. The 27-patient subgroup best represents the. treatment regimen and patient population for Caribou's planned ANTLER-3. -- Caribou previously reached alignment with the U.S. Food and Drug. Administration  regarding its planned ANTLER-3 pivotal phase 3. clinical trial design, which is expected to be a randomized, control","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","CR","BK4230","BK4139","LD","MEDX","PFS","BK4539","CAR","GDOC","SYNB","BK4588","ORR","LFSC","IDNA","BK4585","CRBU","BK4195","FBT","HYLG","BK4022","NVIB","BK4161","GNOM","IBBQ","TBXU","IBB","CNCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659900794","title":"Corcept Chief Development Officer William Guyer Disposes of Common Shares Worth $1.85 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659900794","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659900794?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:27","pubTimestamp":1786566428,"startTime":"0","endTime":"0","summary":"Corcept Chief Development Officer William Guyer disposes of common shares worth $1.85 millionCorcept disclosed Chief Development Officer William Guyer exercised options for 16,300 shares at $ 21.65 on","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL2qSVvx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept Chief Development Officer William Guyer Disposes of Common Shares Worth $1.85 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","FBT","PSCH","CORT","LU1559883803.SGD","BK4007","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658906555","title":"Alkermes Cuts Interest Spreads on $1.52 Billion Term Loan Facilities Via Credit Agreement Amendment","url":"https://stock-news.laohu8.com/highlight/detail?id=2658906555","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658906555?lang=en_us&edition=fundamental","pubTime":"2026-08-12 23:19","pubTimestamp":1786547988,"startTime":"0","endTime":"0","summary":"Alkermes cuts interest spreads on $1.52 billion term loan facilities via credit agreement amendmentAlkermes entered an amendment on Aug. 12, 2026 to its Feb. 12, 2026 credit agreement with JPMorgan Chase Bank.The deal covers senior secured term loan A of USD 745.31 million, due Feb. 12, 2031, and term loan B of USD 773.06 million, due Aug. 12, 2031.The amendment cuts the interest spread by 0.75% on the term loan A facility, 0.5% on the term loan B facility.Term loan A now prices at Term SOFR plus 1.75%-2.25%, or base rate plus 0.75%-1.25%, based on secured net leverage.Term loan B now prices at Term SOFR plus 2.25%, or base rate plus 1.25%.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alkermes plc published the original content used t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL3L5Jbs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2357305700.SGD","LU2106854487.HKD","LU1363072403.SGD","IBRN","TFNS","TRUF","FNCL","LU0211326755.USD","LU0345770993.USD","IYG","IE00BZ1G4Q59.USD","LU2552382132.HKD","ALKS","LU0211331839.USD","LU0234572021.USD","IXG","VFH","JPO","LU1496350502.SGD","LU1116320901.HKD","LU2456880835.USD","UYG","PSCH","LU2462157665.USD","LU0265550946.USD","FTXO","IYF","IE00BYXW3230.USD","LU2237443622.USD","LU1629891620.HKD","MEDX","XLF","LU1720051017.SGD","LU0208291251.USD","LU1551013425.SGD","LU2054465674.USD","LU2505996681.GBP","LU0320765489.SGD","LU0320765646.SGD","LU0496365809.HKD","LU1974910355.USD","LU1162221912.USD","PSIL","LU0106261372.USD","FBT","LU2552382215.SGD","LU2023250843.SGD","KBWB","JPMO","JPX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658908840","title":"Alkermes - Enters Amendment No. 1 to Credit Agreement on August 12, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2658908840","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658908840?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:27","pubTimestamp":1786541257,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4491BU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBRN","BK4139","ALKS","PSIL","PSCH","FBT","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658908808","title":"Alkermes - Amendment Reduces Interest Rate Spread Under Tla by 0.75% and Tlb by 0.50% - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2658908808","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658908808?lang=en_us&edition=fundamental","pubTime":"2026-08-12 21:27","pubTimestamp":1786541257,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4491BU:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBRN","BK4139","ALKS","PSIL","PSCH","FBT","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658945652","title":"NeoGenomics Announces Planned Transition of General Counsel Role","url":"https://stock-news.laohu8.com/highlight/detail?id=2658945652","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658945652?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:30","pubTimestamp":1786480221,"startTime":"0","endTime":"0","summary":"NeoGenomics ( ($NEO) ) has shared an update. NeoGenomics announced on August 11, 2026, that Alicia Olivo, its EVP, General Counsel & Business Devel...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neogenomics-announces-planned-transition-of-general-counsel-role?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neogenomics-announces-planned-transition-of-general-counsel-role?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","LU0106261612.USD","LU0012050646.USD","NEO","FBT","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658657916","title":"Neurogene Advances Rett Gene Therapy Program and Extends Cash Runway to 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2658657916","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658657916?lang=en_us&edition=fundamental","pubTime":"2026-08-11 22:01","pubTimestamp":1786456868,"startTime":"0","endTime":"0","summary":"Neurogene ( ($NGNE) ) just unveiled an announcement. Neurogene reported strong progress in its NGN-401 gene therapy program for Rett syndrome, high...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neurogene-advances-rett-gene-therapy-program-and-extends-cash-runway-to-2029?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neurogene-advances-rett-gene-therapy-program-and-extends-cash-runway-to-2029?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TBXU","LFSC","IBB","IBBQ","BK4585","GNOM","SYNB","CNCR","BK4588","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658550916","title":"Veracyte (VCYT) Dropped, So What Is Behind The Latest Attention?","url":"https://stock-news.laohu8.com/highlight/detail?id=2658550916","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658550916?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:32","pubTimestamp":1786451561,"startTime":"0","endTime":"0","summary":"What the latest quarter means for Veracyte stock\nVeracyte (VCYT) drew fresh attention after reporting second quarter results that included revenue of $150.32 million and net income of $25.49 million, alongside a raised full year 2026 revenue outlook to a range of $590 million to $596 million.\nSee our latest analysis for Veracyte.\nVeracyte's second quarter swing to profitability and higher 2026 revenue guidance have arrived after a mixed stretch for the share price, with a 30 day share price...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vcyt/veracyte/news/veracyte-vcyt-dropped-so-what-is-behind-the-latest-attention","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vcyt/veracyte/news/veracyte-vcyt-dropped-so-what-is-behind-the-latest-attention","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","FBT","VCYT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658997406","title":"Bruker Expands Atinary Collaboration, Makes Minority Investment in AI R&D Firm","url":"https://stock-news.laohu8.com/highlight/detail?id=2658997406","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658997406?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:54","pubTimestamp":1786449245,"startTime":"0","endTime":"0","summary":"Bruker  said Tuesday it has expanded its collaboration with Atinary Technologies and made a minority investment in the artificial intelligence-driven research and development company.Financial terms of the deal were not disclosed.Atinary plans to integrate Chemspeed laboratory automation platforms, Bruker analytical instruments and SciY scientific software into its AI-driven workflows, Bruker said.The companies aim to combine robotics, analytical technologies and AI agents to automate experiment design and accelerate scientific discovery, Bruker added.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CHAT","FBT","ARTY","BK4121","LU1815336091.USD","TINY","QTOC","VTHR","BRKR","AGIX","LU0757428866.USD","AIPO"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}]}}